Published in Eur J Cancer on December 01, 2002
Breast cancer cells produce tenascin C as a metastatic niche component to colonize the lungs. Nat Med (2011) 4.25
Autocrine laminin-5 ligates alpha6beta4 integrin and activates RAC and NFkappaB to mediate anchorage-independent survival of mammary tumors. J Cell Biol (2003) 1.67
Lack of host SPARC enhances vascular function and tumor spread in an orthotopic murine model of pancreatic carcinoma. Dis Model Mech (2009) 1.53
Cellular traction stresses increase with increasing metastatic potential. PLoS One (2012) 1.50
SPARC: a matricellular regulator of tumorigenesis. J Cell Commun Signal (2009) 1.41
RNA interference of ecto-5'-nucleotidase (CD73) inhibits human breast cancer cell growth and invasion. Clin Exp Metastasis (2007) 1.29
Tumour-associated tenascin-C isoforms promote breast cancer cell invasion and growth by matrix metalloproteinase-dependent and independent mechanisms. Breast Cancer Res (2009) 1.28
Mammary epithelial cell interactions with fibronectin stimulate epithelial-mesenchymal transition. Oncogene (2013) 1.22
Epithelial to mesenchymal transition promotes breast cancer progression via a fibronectin-dependent STAT3 signaling pathway. J Biol Chem (2013) 1.15
Tumor lymphangiogenesis and metastasis to lymph nodes induced by cancer cell expression of podoplanin. Am J Pathol (2010) 1.13
The cochaperone p23 differentially regulates estrogen receptor target genes and promotes tumor cell adhesion and invasion. Mol Cell Biol (2006) 1.02
Interaction of calcium-bound C-reactive protein with fibronectin is controlled by pH: in vivo implications. J Biol Chem (2004) 1.00
An "elite hacker": breast tumors exploit the normal microenvironment program to instruct their progression and biological diversity. Cell Adh Migr (2012) 0.99
Evidence for a role of tumor-derived laminin-511 in the metastatic progression of breast cancer. Am J Pathol (2007) 0.98
Laminin-511: a multi-functional adhesion protein regulating cell migration, tumor invasion and metastasis. Cell Adh Migr (2012) 0.95
Controlling matrix stiffness and topography for the study of tumor cell migration. Cell Adh Migr (2012) 0.95
Epigenetic reversion of breast carcinoma phenotype is accompanied by changes in DNA sequestration as measured by AluI restriction enzyme. Am J Pathol (2007) 0.94
Rat mammary extracellular matrix composition and response to ibuprofen treatment during postpartum involution by differential GeLC-MS/MS analysis. J Proteome Res (2012) 0.94
Enhanced interferon signaling pathway in oral cancer revealed by quantitative proteome analysis of microdissected specimens using 16O/18O labeling and integrated two-dimensional LC-ESI-MALDI tandem MS. Mol Cell Proteomics (2009) 0.94
Tumor Cell-Driven Extracellular Matrix Remodeling Drives Haptotaxis during Metastatic Progression. Cancer Discov (2016) 0.94
Thrombospondin-1 expression in urothelial carcinoma: prognostic significance and association with p53 alterations, tumour angiogenesis and extracellular matrix components. BMC Cancer (2006) 0.93
An epigenetically distinct breast cancer cell subpopulation promotes collective invasion. J Clin Invest (2015) 0.91
Gene expression analysis of biological systems driving an organotypic model of endometrial carcinogenesis and chemoprevention. Gene Regul Syst Bio (2008) 0.91
IGFBP-3 can either inhibit or enhance EGF-mediated growth of breast epithelial cells dependent upon the presence of fibronectin. J Biol Chem (2010) 0.91
Immunohistochemical expression of insulin-like growth factor binding protein-3 in invasive breast cancers and ductal carcinoma in situ: implications for clinicopathology and patient outcome. Breast Cancer Res (2004) 0.88
Current and emerging quantitative magnetic resonance imaging methods for assessing and predicting the response of breast cancer to neoadjuvant therapy. Breast Cancer (Dove Med Press) (2012) 0.87
Lymphatic metastasis in breast cancer: importance and new insights into cellular and molecular mechanisms. Clin Exp Metastasis (2007) 0.87
Expression of extracellular matrix proteins in ameloblastomas and adenomatoid odontogenic tumors. Eur Arch Otorhinolaryngol (2009) 0.87
Collagen and elastic fibers in odontogenic entities: analysis using light and confocal laser microscopic methods. Open Dent J (2011) 0.87
Breast Cancer-Associated Fibroblasts: Where We Are and Where We Need to Go. Cancers (Basel) (2016) 0.86
Epithelial-to-mesenchymal transition in breast cancer: a role for insulin-like growth factor I and insulin-like growth factor-binding protein 3? Breast Cancer (Dove Med Press) (2015) 0.85
Prognostic significance of tenascin-C expression in superficial and invasive bladder cancer. J Clin Pathol (2004) 0.85
Extracellular molecules involved in cancer cell invasion. Cancers (Basel) (2015) 0.85
Association of invasion-promoting tenascin-C additional domains with breast cancers in young women. Breast Cancer Res (2010) 0.84
Laminin-111-derived peptides and cancer. Cell Adh Migr (2012) 0.82
Alterations of MicroRNAs in Solid Cancers and Their Prognostic Value. Cancers (Basel) (2010) 0.82
Mesenchymal Stem Cells Induce Directional Migration of Invasive Breast Cancer Cells through TGF-β. Sci Rep (2015) 0.82
Fibronectin affects transient MMP2 gene expression through DNA demethylation changes in non-invasive breast cancer cell lines. PLoS One (2014) 0.81
Laminin isoform expression in breast tumors. Breast Cancer Res (2005) 0.81
A top-down view of the tumor microenvironment: structure, cells and signaling. Front Cell Dev Biol (2015) 0.81
Epithelial-Mesenchymal Transition Phenotype Is Associated with Clinicopathological Factors That Indicate Aggressive Biological Behavior and Poor Clinical Outcomes in Invasive Breast Cancer. J Breast Cancer (2015) 0.81
Tenascin C in metastasis: A view from the invasive front. Cell Adh Migr (2015) 0.81
Tenascin-C and fibronectin expression divide early stage tongue cancer into low- and high-risk groups. Br J Cancer (2017) 0.80
Quantitative analysis of three-dimensional human mammary epithelial tissue architecture reveals a role for tenascin-C in regulating c-met function. Am J Pathol (2009) 0.80
Epigenetic regulation of insulin-like growth factor binding protein-3 (IGFBP-3) in cancer. J Cell Commun Signal (2015) 0.80
Identification of stromal ColXα1 and tumor-infiltrating lymphocytes as putative predictive markers of neoadjuvant therapy in estrogen receptor-positive/HER2-positive breast cancer. BMC Cancer (2016) 0.79
A reconstructed metastasis model to recapitulate the metastatic spread in vitro. Biotechnol J (2014) 0.79
Impact of PINCH expression on survival in colorectal cancer patients. BMC Cancer (2011) 0.79
Collagen density and alignment in responsive and resistant trastuzumab-treated breast cancer xenografts. J Biomed Opt (2015) 0.78
Differential subcellular and extracellular localisations of proteins required for insulin-like growth factor- and extracellular matrix-induced signalling events in breast cancer progression. BMC Cancer (2014) 0.78
Reengineering the Tumor Microenvironment to Alleviate Hypoxia and Overcome Cancer Heterogeneity. Cold Spring Harb Perspect Med (2016) 0.77
Dkk-1 and IL-7 in plasma of patients with multiple myeloma prevent differentiation of mesenchymal stem cells into osteoblasts. Am J Blood Res (2014) 0.77
Biomolecular features of clinical relevance in breast cancer. Eur J Nucl Med Mol Imaging (2004) 0.76
Cross Talk Mechanism among EMT, ROS, and Histone Acetylation in Phorbol Ester-Treated Human Breast Cancer MCF-7 Cells. Oxid Med Cell Longev (2016) 0.76
Mitogen-activated protein kinase signaling causes malignant melanoma cells to differentially alter extracellular matrix biosynthesis to promote cell survival. BMC Cancer (2016) 0.76
High expression of fibronectin is associated with poor prognosis, cell proliferation and malignancy via the NF-κB/p53-apoptosis signaling pathway in colorectal cancer. Oncol Rep (2016) 0.75
Fibronectin induces epithelial-mesenchymal transition in human breast cancer MCF-7 cells via activation of calpain. Oncol Lett (2017) 0.75
From competency to dormancy: a 3D model to study cancer cells and drug responsiveness. J Transl Med (2016) 0.75
High expression of intratumoral stromal proteins is associated with chemotherapy resistance in breast cancer. Oncotarget (2016) 0.75
Mena(INV) dysregulates cortactin phosphorylation to promote invadopodium maturation. Sci Rep (2016) 0.75
Tiamulin inhibits breast cancer growth and pulmonary metastasis by decreasing the activity of CD73. BMC Cancer (2017) 0.75
α1-antitrypsin promotes lung adenocarcinoma metastasis through upregulating fibronectin expression. Int J Oncol (2017) 0.75
Synthetic Capillaries to Control Microscopic Blood Flow. Sci Rep (2016) 0.75
Mesenchymal stem cells from tumor microenvironment favour breast cancer stem cell proliferation, cancerogenic and metastatic potential, via ionotropic purinergic signalling. Sci Rep (2017) 0.75
Non-canonical WNT/PCP signalling in cancer: Fzd6 takes centre stage. Oncogenesis (2017) 0.75
Combinatorial Microenvironments Impose a Continuum of Cellular Responses to a Single Pathway-Targeted Anti-cancer Compound. Cell Rep (2017) 0.75
Diagnostic and therapeutic management of cancer of an unknown primary. Eur J Cancer (2003) 4.22
The current and future role of the medical oncologist in the professional care for cancer patients: a position paper by the European Society for Medical Oncology (ESMO). Ann Oncol (2013) 2.53
Rectal metastases from lobular carcinoma of the breast: report of a case and literature review. Ann Oncol (2001) 2.23
Cancers of unknown primary site: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol (2011) 1.84
EO9 phase II study in advanced breast, gastric, pancreatic and colorectal carcinoma by the EORTC Early Clinical Studies Group. Eur J Cancer (1996) 1.58
Cancer, pregnancy and fertility: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol (2013) 1.52
Taxane resistance in breast cancer: mechanisms, predictive biomarkers and circumvention strategies. Cancer Treat Rev (2012) 1.42
Malignant melanoma of unknown primary site. To make the long story short. A systematic review of the literature. Crit Rev Oncol Hematol (2010) 1.40
Endometrioid carcinoma of the prostate. The diagnostic value of Leu7 and prostatic specific antigen. Br J Urol (1993) 1.38
Carboplatin plus paclitaxel in unknown primary carcinoma: a phase II Hellenic Cooperative Oncology Group Study. J Clin Oncol (2000) 1.31
Docetaxel (Taxotere) is active in non-small-cell lung cancer: a phase II trial of the EORTC Early Clinical Trials Group (ECTG) Br J Cancer (1994) 1.30
Phase II, two-stage, single-arm trial of the histone deacetylase inhibitor (HDACi) romidepsin in metastatic castration-resistant prostate cancer (CRPC). Ann Oncol (2009) 1.27
Phase II trial with S-1 in chemotherapy-naïve patients with gastric cancer. A trial performed by the EORTC Early Clinical Studies Group (ECSG). Eur J Cancer (2003) 1.24
'Classical' but not 'other' mutations of EGFR kinase domain are associated with clinical outcome in gefitinib-treated patients with non-small cell lung cancer. Br J Cancer (2007) 1.23
Cancer, fertility and pregnancy: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol (2010) 1.23
Acute calcific tendinitis of the longus colli muscle: case report and review of the literature. Eur Spine J (2012) 1.17
The insulin-like growth factor-I receptor inhibitor figitumumab (CP-751,871) in combination with docetaxel in patients with advanced solid tumours: results of a phase Ib dose-escalation, open-label study. Br J Cancer (2010) 1.14
Combination chemotherapy with cisplatin-vinblastine in malignant mesothelioma. Lung Cancer (1994) 1.13
Human malignant tumours of the breast, as compared to their respective normal tissue, have elevated expression of the Harvey ras oncogene. Anticancer Res (1984) 1.12
Cavitating squamous cell lung carcinoma-distinct entity or not? Analysis of radiologic, histologic, and clinical features. Lung Cancer (2004) 1.12
The presence of proprioceptive mechanoreceptors in the remnants of the ruptured ACL as a possible source of re-innervation of the ACL autograft. Knee Surg Sports Traumatol Arthrosc (2001) 1.11
ESMO Minimum Clinical Recommendations for diagnosis, treatment and follow-up of non-small-cell lung cancer (NSCLC). Ann Oncol (2005) 1.10
The diagnosis and management of gastric cancer: expert discussion and recommendations from the 12th ESMO/World Congress on Gastrointestinal Cancer, Barcelona, 2010. Ann Oncol (2011) 1.10
Prevention of chemotherapy-induced alopecia using an effective scalp cooling system. Eur J Cancer (2000) 1.08
Noncardiogenic pulmonary edema: an unusual and serious complication of anticancer therapy. Oncologist (2001) 1.07
Patients with multiple myeloma and solid tumors: six case reports. J Exp Clin Cancer Res (1998) 1.07
Updated diagnostic criteria for partial and complete hydatidiform moles in early pregnancy. Anticancer Res (2003) 1.02
Randomised trials comparing chemotherapy regimens for advanced non-small cell lung cancer: biases and evolution over time. Eur J Cancer (2003) 1.02
p63 expression in benign and malignant breast lesions. Histol Histopathol (2004) 1.01
ESMO Minimum Clinical Recommendations for diagnosis, treatment and follow-up of malignant glioma. Ann Oncol (2005) 1.00
Diffuse large cell lymphomas: identification of prognostic factors and validation of the International Non-Hodgkin's Lymphoma Prognostic Index. A Hellenic Cooperative Oncology Group Study. Oncology (1998) 1.00
A randomized trial to compare the efficacy and safety of antiemetic treatment with ondansetron and ondansetron zydis in patients with breast cancer treated with high-dose epirubicin. Anticancer Res (2008) 0.99
Evaluation of the prognostic and predictive value of HER family mRNA expression in high-risk early breast cancer: a Hellenic Cooperative Oncology Group (HeCOG) study. Br J Cancer (2008) 0.99
Cisplatin/etoposide versus carboplatin/etoposide chemotherapy and irradiation in small cell lung cancer: a randomized phase III study. Hellenic Cooperative Oncology Group for Lung Cancer Trials. Semin Oncol (1994) 0.99
Prognostic significance of UBE2C mRNA expression in high-risk early breast cancer. A Hellenic Cooperative Oncology Group (HeCOG) Study. Ann Oncol (2011) 0.99
NT5E (CD73) is epigenetically regulated in malignant melanoma and associated with metastatic site specificity. Br J Cancer (2012) 0.98
Cancer and pregnancy: a comprehensive review. Surg Oncol (2011) 0.97
The missing kiss of life: transcriptional activity of the metastasis suppressor gene KiSS1 in early breast cancer. Anticancer Res (2007) 0.96
The MAPK-AP-1/-Runx2 signalling axes are implicated in chondrosarcoma pathobiology either independently or via up-regulation of VEGF. Histopathology (2005) 0.96
Cancer, fertility and pregnancy: ESMO clinical recommendations for diagnosis, treatment and follow-up. Ann Oncol (2009) 0.96
Immunohistochemical expression of superoxide dismutase (MnSOD) anti-oxidant enzyme in invasive breast carcinoma. Histol Histopathol (2004) 0.96
NT5E CpG island methylation is a favourable breast cancer biomarker. Br J Cancer (2012) 0.96
ESMO Minimum Clinical Recommendations for diagnosis, treatment and follow-up of cancers of unknown primary site (CUP). Ann Oncol (2005) 0.95
Increased expression of the bcl6 and CD10 proteins is associated with increased apoptosis and proliferation in diffuse large B-cell lymphomas. Mod Pathol (2003) 0.95
Immunohistochemical study of angiogenesis and proliferative activity in epiretinal membranes. Int J Clin Pract (2005) 0.95
Primary extranodal non-Hodgkin's lymphoma of the head and neck. Oncology (1992) 0.94
hMSH2 is the most commonly mutated MMR gene in a cohort of Greek HNPCC patients. Br J Cancer (2005) 0.94
Thyroid disease in Sjögren's syndrome. Arthritis Rheum (1980) 0.94
Cancers of unknown primary site: ESMO clinical recommendation for diagnosis, treatment and follow-up. Ann Oncol (2008) 0.93
Intratumoral CRH modulates immuno-escape of ovarian cancer cells through FasL regulation. Br J Cancer (2007) 0.93
Effects of hormonal treatment on lipids in patients with cancer. Cancer Treat Rev (2008) 0.93
Vascular endothelial growth factor polymorphisms and clinical outcome in colorectal cancer patients treated with irinotecan-based chemotherapy and bevacizumab. Pharmacogenomics J (2011) 0.92
A randomized phase III study comparing three anthracycline-free taxane-based regimens, as first line chemotherapy, in metastatic breast cancer: a Hellenic Cooperative Oncology Group study. Breast Cancer Res Treat (2008) 0.91
Low-grade mucosa-associated lymphoid tissue lymphoma: a retrospective analysis of 97 patients by the Hellenic Cooperative Oncology Group (HeCOG). Ann Oncol (2007) 0.91
Lung cancer in pregnancy: report of nine cases from an international collaborative study. Lung Cancer (2013) 0.90
Heterogeneity in cancer guidelines: should we eradicate or tolerate? Ann Oncol (2008) 0.90
Fluorouracil and leucovorin with or without interferon alfa-2b in advanced colorectal cancer: analysis of a prospective randomized phase III trial. Hellenic Cooperative Oncology Group. J Clin Oncol (1996) 0.89
Renal cell carcinoma in pregnancy: a rare coexistence. Clin Transl Oncol (2013) 0.89
Prognostic significance of RACGAP1 mRNA expression in high-risk early breast cancer: a study in primary tumors of breast cancer patients participating in a randomized Hellenic Cooperative Oncology Group trial. Cancer Chemother Pharmacol (2012) 0.89
Stress-induced impairment of macrophage tumoricidal function. Psychosom Med (1980) 0.88
Combination regimen with carboplatin, epirubicin and etoposide in metastatic carcinomas of unknown primary site: A Hellenic Co-Operative Oncology Group Phase II Study. Oncology (1998) 0.88
Clinicopathologic study of vascular endothelial growth factor, thrombospondin-1, and microvessel density assessed by CD34 in patients with stage III ovarian carcinoma. Int J Gynecol Cancer (2006) 0.88
Paclitaxel-carboplatin combination chemotherapy in advanced breast cancer: accumulating evidence for synergy, efficacy, and safety. Med Oncol (2006) 0.88
Immunohistochemical expression of p53, p21/waf1, rb, p16, cyclin D1, p27, Ki67, cyclin A, cyclin B1, bcl2, bax and bak proteins and apoptotic index in normal thymus. Histol Histopathol (2001) 0.88
Clinicopathological study of the expression of syndecan-1 in invasive breast carcinomas. correlation with extracellular matrix components. J Exp Clin Cancer Res (2004) 0.88
Phase II clinical trials with rhizoxin in breast cancer and melanoma. The EORTC Early Clinical Trials Group. Br J Cancer (1996) 0.88
Epithelial ovarian carcinoma in younger vs older women: is age an independent prognostic factor? The Hellenic Oncology Cooperative Group experience. Int J Gynecol Cancer (2007) 0.88
Expression of vascular endothelial growth factor (VEGF) and association with microvessel density in small-cell and non-small-cell lung carcinomas. Histol Histopathol (2004) 0.87
Favorable outcome of ovarian germ cell malignancies treated with cisplatin or carboplatin-based chemotherapy: a Hellenic Cooperative Oncology Group study. Gynecol Oncol (1998) 0.87
CD44 family and gynaecological cancer. In Vivo (2004) 0.87
Non-small cell lung cancer in the young: a retrospective analysis of diagnosis, management and outcome data. Anticancer Res (2006) 0.87
Glufosfamide administered using a 1-hour infusion given as first-line treatment for advanced pancreatic cancer. A phase II trial of the EORTC-new drug development group. Eur J Cancer (2003) 0.87
Immunohistochemical study of extracellular matrix components in epiretinal membranes of vitreoproliferative retinopathy and proliferative diabetic retinopathy. Eur J Ophthalmol (2005) 0.86
Immunohistochemical expression of Bcl-2 protein in breast lesions: correlation with Bax, p53, Rb, C-erbB-2, EGFR and proliferation indices. Anticancer Res (2001) 0.86
E-cadherin adhesion molecule and syndecan-1 expression in various thyroid pathologies. Exp Oncol (2007) 0.86
Triple-negative phenotype is of adverse prognostic value in patients treated with dose-dense sequential adjuvant chemotherapy: a translational research analysis in the context of a Hellenic Cooperative Oncology Group (HeCOG) randomized phase III trial. Cancer Chemother Pharmacol (2011) 0.86
Tumor volumetry as predictive and prognostic factor in the management of ovarian cancer. Anticancer Res (2002) 0.86
Mucoepidermoid carcinoma of the thymus: a case presentation and a literature review. Pathol Res Pract (2004) 0.86
Cancers of unknown primary site: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol (2010) 0.86
Docetaxel and gemcitabine in anthracycline-resistant advanced breast cancer: a Hellenic Cooperative Oncology Group Phase II study. Cancer Invest (2000) 0.86
Clinical significance of low creatine phosphokinase values in patients with connective tissue diseases. JAMA (1981) 0.85
Targeting c-KIT, PDGFR in cancer of unknown primary: a screening study for molecular markers of benefit. J Cancer Res Clin Oncol (2007) 0.85